March 27, 2017 2:07 AM ET

Biotechnology

Company Overview of EPIRUS Biopharmaceuticals, Inc.

Company Overview

EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company’s pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid art...

699 Boylston Street

Eighth Floor

Boston, MA 02116

United States

Founded in 2011

73 Employees

Phone:

617-600-3497

Key Executives for EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals, Inc. does not have any Key Executives recorded.

EPIRUS Biopharmaceuticals, Inc. Key Developments

Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.

The US Bankruptcy Court approved the sale of certain assets of Epirus Biopharmaceuticals, Inc. on September 19, 2016. As per the order, debtor has been authorized to sell BOW080 materials, intellectual property and rights to Orphonix, Inc. for $0.95 million, as per the agreement dated September 9, 2016. Buyer has deposited 10% of the purchase price as deposit. Trustee will remit $0.63 million to Hercules from the sale proceeds.

EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index

EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index

EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index

EPIRUS Biopharmaceuticals, Inc. has been removed from Nasdaq Composite Index.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Bankruptcy
July 25, 2016
--
Merger/Acquisition
June 14, 2016
EPIRUS Biopharmaceuticals (Netherlands) B.V.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EPIRUS Biopharmaceuticals, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.